The total number of records retrieved from this search are 20. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
OV_4170	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	Yes	No	No	ATCC	Human breast cancer cell line	MDA 231-lu-PA	5000 cells per well	NA	MTT assay	0.1 MOI	100% cell viability after 24 hours	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4171	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	Yes	No	No	ATCC	Human breast cancer cell line	MDA 231-lu-PA	5000 cells per well	NA	MTT assay	0.1 MOI	90% cell viability after 48 hours	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4172	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	Yes	No	No	ATCC	Human breast cancer cell line	MDA 231-lu-PA	5000 cells per well	NA	MTT assay	0.1 MOI	70% cell viability after 72 hours	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4173	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	Yes	No	No	ATCC	Human breast cancer cell line	MDA 231-lu-PA	5000 cells per well	NA	MTT assay	0.1 MOI	40% cell viability after 6 days	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4174	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	Yes	No	No	ATCC	Human breast cancer cell line	MDA 231-lu-PA	5000 cells per well	NA	MTT assay	0.1 MOI	30% cell viability after 7 days	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4175	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	Yes	No	No	ATCC	Human breast cancer cell line	MDA 231-lu-PA	5000 cells per well	NA	MTT assay	1 MOI	100% cell viability after 24 hours	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4176	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	Yes	No	No	ATCC	Human breast cancer cell line	MDA 231-lu-PA	5000 cells per well	NA	MTT assay	1 MOI	50% cell viability after 48 hours	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4177	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	Yes	No	No	ATCC	Human breast cancer cell line	MDA 231-lu-PA	5000 cells per well	NA	MTT assay	1 MOI	20% cell viability after 72 hours	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4178	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	Yes	No	No	ATCC	Human breast cancer cell line	MDA 231-lu-PA	5000 cells per well	NA	MTT assay	1 MOI	10% cell viability after 6 days	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4179	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	Yes	No	No	ATCC	Human breast cancer cell line	MDA 231-lu-PA	5000 cells per well	NA	MTT assay	1 MOI	10% cell viability after 7 days	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4180	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	No	Virus in combination with Alisertib (70nM) before 2 hours of MV infection	No	ATCC	Human breast cancer cell line	MDA 231-lu-PA	5000 cells per well	NA	MTT assay	0.1 MOI	100% cell viability after 24 hours	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4181	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	No	Virus in combination with Alisertib (70nM) before 2 hours of MV infection	No	ATCC	Human breast cancer cell line	MDA 231-lu-PA	5000 cells per well	NA	MTT assay	0.1 MOI	80% cell viability after 48 hours	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4182	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	No	Virus in combination with Alisertib (70nM) before 2 hours of MV infection	No	ATCC	Human breast cancer cell line	MDA 231-lu-PA	5000 cells per well	NA	MTT assay	0.1 MOI	58% cell viability after 72 hours	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4183	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	No	Virus in combination with Alisertib (70nM) before 2 hours of MV infection	No	ATCC	Human breast cancer cell line	MDA 231-lu-PA	5000 cells per well	NA	MTT assay	0.1 MOI	20% cell viability after 6 days	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4184	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	No	Virus in combination with Alisertib (70nM) before 2 hours of MV infection	No	ATCC	Human breast cancer cell line	MDA 231-lu-PA	5000 cells per well	NA	MTT assay	0.1 MOI	100% cell killing after 7 days	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4185	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	No	Virus in combination with Alisertib (70nM) before 48 hours of MV infection	No	ATCC	Human breast cancer cell line	MDA 231-lu-PA	5000 cells per well	NA	MTT assay	1 MOI	100% cell viability after 24 hours	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4186	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	No	Virus in combination with Alisertib (70nM) before 48 hours of MV infection	No	ATCC	Human breast cancer cell line	MDA 231-lu-PA	5000 cells per well	NA	MTT assay	1 MOI	50% cell viability after 48 hours	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4187	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	No	Virus in combination with Alisertib (70nM) before 48 hours of MV infection	No	ATCC	Human breast cancer cell line	MDA 231-lu-PA	5000 cells per well	NA	MTT assay	1 MOI	10% cell viability after 72 hours	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4188	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	No	Virus in combination with Alisertib (70nM) before 48 hours of MV infection	No	ATCC	Human breast cancer cell line	MDA 231-lu-PA	5000 cells per well	NA	MTT assay	1 MOI	100% cell killing after 6 days	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026
OV_4189	Measles virus	MV-s-NAP	RNA	Paramyxoviridae	Genetically engineered for expressing H.pylori neutophil activating protein	No	Virus in combination with Alisertib (70nM) before 48 hours of MV infection	No	ATCC	Human breast cancer cell line	MDA 231-lu-PA	5000 cells per well	NA	MTT assay	1 MOI	100% cell killing after 7 days	No	No	NA	No response	NA	Virus induce apoptosis process leads to cancer cell death	Virus and drug both cause induction of IL-24 expression	In clinical trials	26272026